Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Topoisomerase II and the etiology of chromosomal translocations.

Felix CA, Kolaris CP, Osheroff N.

DNA Repair (Amst). 2006 Sep 8;5(9-10):1093-108. Epub 2006 Jul 20. Review.

PMID:
16857431
2.

Etoposide, topoisomerase II and cancer.

Baldwin EL, Osheroff N.

Curr Med Chem Anticancer Agents. 2005 Jul;5(4):363-72. Review.

PMID:
16101488
3.

Apoptosis induced by topoisomerase inhibitors.

Sordet O, Khan QA, Kohn KW, Pommier Y.

Curr Med Chem Anticancer Agents. 2003 Jul;3(4):271-90. Review.

PMID:
12769773
4.

DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic.

Holden JA.

Curr Med Chem Anticancer Agents. 2001 May;1(1):1-25. Review.

PMID:
12678768
5.

Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.

Wilstermann AM, Osheroff N.

Curr Top Med Chem. 2003;3(3):321-38. Review.

PMID:
12570766
6.

NMR in drug discovery.

Pellecchia M, Sem DS, W├╝thrich K.

Nat Rev Drug Discov. 2002 Mar;1(3):211-9. Review.

PMID:
12120505
7.

Cellular roles of DNA topoisomerases: a molecular perspective.

Wang JC.

Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40. Review.

PMID:
12042765
9.

DNA topoisomerases: structure, function, and mechanism.

Champoux JJ.

Annu Rev Biochem. 2001;70:369-413. Review.

PMID:
11395412
10.

Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA.

Leroy D, Kajava AV, Frei C, Gasser SM.

Biochemistry. 2001 Feb 13;40(6):1624-34.

PMID:
11327821
11.

DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.

Byl JA, Cline SD, Utsugi T, Kobunai T, Yamada Y, Osheroff N.

Biochemistry. 2001 Jan 23;40(3):712-8.

PMID:
11170388
12.

Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.

Fortune JM, Osheroff N.

Prog Nucleic Acid Res Mol Biol. 2000;64:221-53. Review.

PMID:
10697411
13.

Affinity NMR.

Chen A, Shapiro MJ.

Anal Chem. 1999 Oct 1;71(19):669A-675A. Review.

PMID:
10517136
14.

Anticancer drug design based on plant-derived natural products.

Lee KH.

J Biomed Sci. 1999 Jul-Aug;6(4):236-50. Review.

PMID:
10420081
15.

Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.

Kingma PS, Burden DA, Osheroff N.

Biochemistry. 1999 Mar 23;38(12):3457-61.

PMID:
10090731
16.

NMR spectroscopy in structure-based drug design.

Roberts GC.

Curr Opin Biotechnol. 1999 Feb;10(1):42-7. Review.

PMID:
10047507
17.

The critical role of chromosome translocations in human leukemias.

Rowley JD.

Annu Rev Genet. 1998;32:495-519. Review.

PMID:
9928489
18.

Etoposide: four decades of development of a topoisomerase II inhibitor.

Hande KR.

Eur J Cancer. 1998 Sep;34(10):1514-21. Review.

PMID:
9893622
19.

Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine.

Wang JC.

Q Rev Biophys. 1998 May;31(2):107-44. Review. No abstract available.

PMID:
9794033
20.

Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death.

Larsen AK, Skladanowski A.

Biochim Biophys Acta. 1998 Oct 1;1400(1-3):257-74. Review.

PMID:
9748618

Supplemental Content

Support Center